VEGFR2/CD309 anticorps (pTyr1175)

N° du produit ABIN318151

Détail du produit anti-VEGFR2/CD309 anticorps

Antigène: VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))

Épitope: pTyr1175

Reactivité: Humain, Souris, Rat

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp VEGFR2/CD309 est non-conjugé

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Specificité: This antibody reacts to CD309 / VEGFR-2 / Flk-1 only when phosphorylated at Tyr1214.

Purification: Affinity chromatography

Information d'application

Indications d'application: Immunohistochemistry: 1/50 - 1/200. ELISA.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Stockage

Concentration: 1,0 mg/mL

Buffer: Phosphate buffered saline (PBS) with 0.05 % sodium azide, approx. pH 7.2.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Avoid repeated freezing and thawing.

Stock: 4 °C/-20 °C

Stockage commentaire: Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.

Détails sur VEGFR2/CD309

Antigène: VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))

Autre désignation: CD309 / VEGFR-2 / Flk-1 (VEGFR2 Produits)

Synonymes: anticorps CD309, anticorps FLK1, anticorps VEGFR, anticorps VEGFR2, anticorps 6130401C07, anticorps Flk-1, anticorps Flk1, anticorps Krd-1, anticorps Ly73, anticorps VEGFR-2, anticorps sVEGFR-2, anticorps Vegfr-2, anticorps FLK-1, anticorps flk-1, anticorps vegfr-2, anticorps KDR, anticorps FLK/KDR, anticorps flk1, anticorps flk1b, anticorps kdrb, anticorps si:busm1-205d10.1, anticorps si:ch211-254j6.1, anticorps si:ch211-278f21.4, anticorps wu:fc31a09, anticorps fk52c05, anticorps flk, anticorps kdr, anticorps kdra, anticorps vegfr2, anticorps vegfr4, anticorps vegr2, anticorps wu:fk52c05, anticorps kinase insert domain receptor, anticorps kinase insert domain protein receptor, anticorps vascular endothelial growth factor receptor kdr-like, anticorps kinase insert domain receptor (a type III receptor tyrosine kinase), anticorps kinase insert domain receptor like, anticorps KDR, anticorps Kdr, anticorps LOC100136647, anticorps kdr, anticorps kdrl

Sujet: Epidermal growth factor mediates its effects on cell growth through its interaction with a cell surface glycoprotein designated the EGF receptor. Binding of EGF or TGFalpha to the EGF receptor activates tyrosine-specific protein kinase activity intrinsic to the EGF receptor. The carboxy-terminal tyrosine residues on EGFR, Tyr 1068 and Tyr 1173 are the major sites of autophosphorylation, which occurs as a result of EGF binding. Once activated, EGFR mediates the binding of the phosphotyrosine binding (PTB) domain of GRB2 through direct interactions with Tyr 1068 and Tyr 1086 and through indirect interactions with Tyr 1173 in the Ras signaling pathway. Tyr 1173 of EGFR also functions as a kinase substrate. Phosphorylation of Tyr 992, Tyr 1068 and Tyr 1086 is required for conformational change in the C-terminal tail of the EGF receptor.Synonyms: FLK1, KDR, Kinase NYK, Kinase insert domain receptor, Protein-tyrosine kinase receptor Flk-1, VEGF Receptor 2, VEGFR2, Vascular endothelial growth factor receptor 2

Poids moléculaire: approx. 230 kDa

ID gène: 3791

NCBI Accession: NP_002244

UniProt: P35968

Pathways: Signalisation RTK, Glycosaminoglycan Metabolic Process, Signaling Events mediated by VEGFR1 and VEGFR2, Growth Factor Binding, Regulation of long-term Neuronal Synaptic Plasticity, VEGF Signaling